ENERGY COVID-19 COLLAPSE: NEW DIAGNOSTIC MARKERS, TREATMENT ASPECTS

Authors

  • Salivonchik D.P
  • Salivonchik E.I

Keywords:

COVID-19, lactate overproduction, energy collapse, thiotriazoline

Abstract

An independent diagnostic criterion for assessing the prognosis in patients with COVID-19 is the dynamics of lactate levels, the overproduction of which is due to the crisis of energy-producing systems and an overload of the glycolytic pathway of energy production. The only corrector for the energy collapse caused by COVID-19 is the use of thiotriazoline, a metabolic drug with multiple pathways for lactate utilization and stimulation of oxidative phosphorylation, with powerful antioxidant properties. Such drugs as blockers of fatty acid metabolism (trimetazidine, meldonium) in this situation have no pathogenetic and biochemical substantiation.

References

Xong T-Y. (2020) Coronaviruses and the cardiovascular system: acute and long-term implication. European Heart Journal, ehaa231. http// doi org/10.1093/eurheart/ehaaa231. Published: 18 March.

Li B. (2020) Prevalence and impact of cardiovascular metabolic Diseases on COVID-19 in China. Clin Res Cardiol., Mar 11. doi: 10.1007/s00392-020-01626-9.

Severin E.S. (2008) Biologicheskaya himiya []. M.: OOO "Medicinskoe informacionnoe agentstvo", 364 p. (in Russian)

Valenza F. (2005) Lactat as a marker of energy failure in critically ill patients: hypothesis. Critical Care, vol. 5, no 6, pp. 588–593.

Poole R.C. (1993) Transport of lactate and other monocarboxylates across mammalian plasma membranes. American Journal of Physiology, vol. 264, pp. 761–782.

Hashimoto T., Brooks G.A. (2008) Mitochondrial lactate oxidation complex and an adaptive role for lactate production. Med Sci Sports Exerc., Mar., vol. 40(3), pp. 486–94.

(2013) Eur Heart J., vol. 34, pp. 2949–3003. doi: 10.1093 / eurheartj/eht296.

Mazur I.A. (2005) Tiotriazolin. Zaporozh'e, 146 p. (in Russian)

Netyazhenko V.Z., Mal'chevskaya T.I. (2010) Vozmozhnosti metabolicheskoj terapii v lechenii ishemicheskoj bolezni serdca: opyt dvojnogo slepogo randomizirovannogo mul'ticentrovogo issledovaniya []. Listapad, no 22 (251), pp. 1–5.

Published

2021-07-23